LED Medical Diagnostics Inc. Strengthens Partnership With Ray Company, Ltd. - Seite 2

About Ray (Ray Company, Ltd.)

Since 2004, Ray has specialized in researching, developing and producing high-quality digital imaging systems for the medical and dental industries. Due to the company's development of superior imaging technology, Ray became a subsidiary of worldwide technology leader Samsung Electronics Co., Ltd, in 2010. Under the Samsung brand, Ray launched the Rayscan Alpha -- Expert in 2012 and rapidly penetrated the US market in 2014. With the success of the Rayscan Alpha, Ray made the strategic decision to become an independent imaging company in 2015, singularly focused on its future as a leader in the worldwide dental imaging market. 

About LED Medical Diagnostics Inc.

Founded in 2003 and headquartered in Burnaby, British Columbia, Canada, LED Medical Diagnostics Inc., through its wholly-owned subsidiaries LED Dental Inc. and LED Dental Ltd, provide dentists and oral health specialists with advanced diagnostic imaging products and software, in addition to the award-winning VELscope® Vx tissue fluorescence visualization technology. Backed by an experienced leadership team and dedicated to a higher level of service and support, LED Dental is committed to providing dental practitioners with the best technology available by identifying and adding leading products to its growing portfolio.

LED Medical Diagnostics, Inc. is currently listed on the Toronto Stock Exchange (TSX-V) under the symbol "LMD," the OTCQX under the symbol "LEDIF," as well as the Frankfurt Stock Exchange under the symbol "LME." For more information, call 844.952.7327 or visit www.leddental.com/investor-relations.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements
This press release contains statements which, to the extent that they are not recitations of historical fact, may constitute forward-looking information under applicable Canadian securities legislation that involve risks and uncertainties. Such forward-looking statements or information include statements regarding, but not limited to the Company's future growth strategy, its distribution strategy and product offerings, potential expansion of the Company's technology to other medical applications or markets, or the potential introduction of new technologies by the Company. Persons reading this press release are cautioned that such statements or information are only predictions, and that the Corporation's actual future results or performance may be materially different. Factors that could cause actual events or results to differ materially from those suggested by these forward-looking statements include, but are not limited to competition risks, distributor risks, product development risks such as regulatory, design, intellectual property and other factors described in the Corporation's reports filed on SEDAR including its Annual Information Form and financial report for the year ended December 31, 2013. These and other factors should be considered carefully and readers should not place undue reliance on such forward-looking information. All forward-looking statements made in this press release are qualified by this cautionary statement and there can be no assurance that actual results or developments anticipated by the Company will be realized. The Company disclaims any intention or obligation to update or revise forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.